Business Development

Business Development & Partnering

Presidio actively evaluates in-licensing opportunities for programs and compounds of all development stages, with a preference for orally bioavailable, small molecule inhibitors. Our primary focus is on inhibitors for HCV and HIV, but we are also evaluating opportunities in other viral areas like RSV, HPV, and the herpes viruses.

Presidio is also open to selective out-licensing and partnership discussions for our current programs.

If you are interested in business development and partnering opportunities with Presidio, please contact:

Omar K. Haffar, Ph.D.
President & CEO
Phone: 415-655-7560
Email:


	Business Development & Partnering Presidio actively evaluates in-licensing opportunities for programs and compounds of all development stages, with a preference for orally bioavailable, small molecule inhibitors. Our primary focus is on inhibitors for HCV and HIV, but we are also evaluating opportunities in other viral areas like RSV, HPV, and the herpes viruses. Presidio is also open to selective out-licensing and partnership discussions for our current programs. If you are interested in business development and partnering opportunities with Presidio, please contact: Omar K. Haffar, Ph.D. President & CEO Phone: 415-655-7560 Email: Presidio Pharmaceuticals, Inc.